The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Chico Colosimo says ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic cancer. This device, called Optune Pax, sends alternating electric fields to the ...

Carolyn Gusoff has covered some of the most high profile news stories in the New York City area and is best known as a trusted, tenacious, consistent and caring voice of Long Island's concerns. For ...

In a phase 3 trial, Optune Pax plus gem/nab-pac significantly improved median overall survival to 16.2 months vs 14.2 months with chemotherapy alone. The Food and Drug Administration (FDA) has ...

The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of ...

The FDA gave the go-ahead to Novocure for its tumor-treating electric fields device that targets advanced pancreatic cancer in conjunction with the drugs gemcitabine and nab-paclitaxel. (Novocure) The ...